Finally, individual differences in baseline metabolic rate and prior exposure to dietary or behavioral weight loss strategies may influence the magnitude of BW reduction achieved with GLP-1 RAs, highlighting the complexity of therapeutic response in patients with T2DM [45]
As PTDM and chronic kidney disease are prevalent comorbidities in liver transplant patients, and with the increasing trend of obesity, it is crucial to further investigate and understand the potential benefits and challenges of utilizing GLP-1 RAs and SGLT-2 inhibitors in this population
Proceeds earned go toward supporting our mission
Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al
Slinic employs a robust safety-netting protocol
[DOI] [PMC free article] [PubMed] [Google Scholar] 164.Lenz M, Galanis C, Mller-Dahlhaus F, Opitz A, Wierenga CJ, Szab G, et al